Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer

A codon and virus technology, applied in the field of recombinant viruses with deoptimized regions of codon pairs and their use in the treatment of cancer, can solve the problem of no effect on short-term or long-term survival of patients, long-term side effects of retroviral therapy, and insertion inducement. change, etc.

Pending Publication Date: 2020-08-07
CODAGENIX INC
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the experimental therapy had no effect on the short- or long-term survival of affected patients
Retroviral therapy is often associated with the risk of serious long-term side effects (eg, insertional mutagenesis)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
  • Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
  • Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0359] Modification of the PV sequence to alter the codon biscore relative to human codon pair bias.

[0360] Our algorithm was given as input the DNA coding sequence of the P1 structural region of poliovirus type 1 Mahoney strain (PV(M)-wt), and the CPB of this region was modified ( figure 2 ). After shuffling using simulated annealing, we generated two new fragments with shuffled codons and thus new codon pairs. The first was designed as PV-Max with a positive CPB of +0.246. This positive CPB indicates that PV-Max uses the overrepresented codon pairs on average. The second was designed as PV-Min with a negative CPB of -0.474. This negative CPB indicates that PV-Min utilizes on average the underrepresented codon pairs ( figure 1 ). The first four codons (12 nucleotides) of PV-Min and PV-Max were unchanged and remained the same as wild-type poliovirus codons. This is done so that translations can be started equally across all entities. Likewise, the P1 region was chos...

Embodiment 2

[0363] Construction of codon pair deoptimized poliovirus

[0364] Plasmids containing the cDNA of synthetic recombinant viruses of the above genotypes or any other variants are amplified, purified and linearized by digestion with the restriction endonuclease FspI (which cleaves within the vector sequence). The resulting linearized cDNA (containing the recognition motif for DNA-dependent RNA polymerase T7 prior to the 5' insertion site of the viral cDNA) was used for in vitro transcription using T7 polymerase to generate full-length viral RNA. The resulting viral RNA was used to transfect HeLa cells by the Dextran-sulfate method to generate infectious virus. Cytopathic effect of transfected cells was observed, indicating productive modified virus infection, and infectious virus was propagated in HeLa cells, purified and frozen for indefinite storage.

Embodiment 3

[0366] The modified virus was attenuated compared to the wild-type virus, but it grew and killed adenocarcinoma cervical cancer HeLa R19 cells.

[0367] After transfection of five PV-Min-derived RNAs into HeLa R19 cells, each product virus was passaged twice to ensure that the viruses were properly amplified, since RNA transfection was not as efficient as natural infection by the virus itself. Next, plaque analysis was performed to clarify the apparent PFU / ml titer (apparent PFU / ml titer) of each virus ( image 3 ). These subclones produced viruses with varying degrees of attenuation. Viruses containing P1 fragments X and Y were each attenuated by 0.8-1 log 10 ; however, when added together, they produced the virus PV-MinXY, which was significantly attenuated by 2.5 orders of magnitude. Virus PV-MinZ is also attenuated by 2.5log like PV-MinXY 10about. Thus, construct PV-YZ failed to produce viable virus when the Y segment was returned to PV-MinZ ( image 3 ). These vary...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regionsof the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or thatincreases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchialpassage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.

Description

[0001] Cross References to Related Applications [0002] Pursuant to 35 U.S.C. §119(e), this application consists of U.S. Provisional Patent Application No. 62 / 609,945, filed December 22, 2017, U.S. Provisional Patent Application No. 62 / 640,362, filed March 8, 2018, 2018 U.S. Provisional Patent Application No. 62 / 677,132, filed May 28, 2018, and U.S. Provisional Patent Application No. 62 / 640,355, filed March 8, 2018, each of which is hereby incorporated by reference All content incorporated. technical field [0003] The present invention relates to modified viruses comprising a modified viral genome comprising multiple nucleotide substitutions for use in the treatment of cancer. Nucleotide substitutions result in codons being replaced by other synonymous codons and / or codon rearrangements and changes in codon pair bias. These modified viruses are used to treat malignancies. Background technique [0004] All publications herein are incorporated by reference to the same ext...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/12A61K39/125
CPCA61K39/12A61K2039/5254C12N2760/16132C12N2770/24134C12N2770/32632A61P31/14A61P35/00A61K2039/876A61K2039/86A61K2039/812Y02A50/30A61K39/125A61K39/13A61K39/145A61K39/3955A61K39/39558C12N7/00C07K16/2827A61K2039/505
Inventor 约翰·罗伯特·科尔曼斯特芬·穆勒杨晨王颖查尔斯·斯塔夫
Owner CODAGENIX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap